期刊
HUMAN MOLECULAR GENETICS
卷 22, 期 23, 页码 4739-4747出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddt327
关键词
-
资金
- Medical Research Centre for Neuromuscular Diseases, Newcastle University Centre for Brain Ageing and Vitality
- Biotechnology and Biological Sciences Research Council
- Engineering and Physical Sciences Research Council
- Medical Research Council as part of the cross-council Lifelong Health and Wellbeing Initiative [G0700718]
- Wellcome Trust Centre for Mitochondrial Research [906919]
- Newcastle NIHR Biomedical Research Centre
- RCUK
- MRC [G1000848, MR/K000608/1, G0700718] Funding Source: UKRI
- Medical Research Council [MR/K000608/1B, G0700718, MR/K000608/1, G1000848] Funding Source: researchfish
Progressive myopathy is a major clinical feature of patients with mitochondrial DNA (mtDNA) disease. There is limited treatment available for these patients although exercise and other approaches to activate muscle stem cells (satellite cells) have been proposed. The majority of mtDNA defects are heteroplasmic (a mixture of mutated and wild-type mtDNA present within the muscle) with high levels of mutated mtDNA and low levels of wild-type mtDNA associated with more severe disease. The culture of satellite cell-derived myoblasts often reveals no evidence of the original mtDNA mutation although it is not known if this is lost by selection or simply not present in these cells. We have explored if the mtDNA mutation is present in the satellite cells in one of the commonest genotypes associated with mitochondrial myopathies (patients with single, large-scale mtDNA deletions). Analysis of satellite cells from eight patients showed that the level of mtDNA mutation in the satellite cells is the same as in the mature muscle but is most often subsequently lost during culture. We show that there are two periods of selection against the mutated form, one early on possibly during satellite cell activation and the other during the rapid replication phase of myoblast culture. Our data suggest that the mutations are also lost during rapid replication in vivo, implying that strategies to activate satellite cells remain a viable treatment for mitochondrial myopathies in specific patient groups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据